Abstract
for interim injections if they fulfilled the retreatment criteria. At each visit, best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) central macular thickness (CMT) were measured. Results: Forty-six patients reached study completion at week 96. Mean BCVA had improved by 6.0 (standard deviation [SD] 7.9) and 4.8 (SD 7.4) ETDRS letters at 52 (p = 0.003) and 96 (p = 0.02) weeks, respectively, from a baseline of 57.3 (SD 12.0) letters. At 52-and 96-week time points, 45/46 (98%) and 41/46 (89%) of patients, respectively, had maintained their vision (< 15 letters of BCVA lost). At the 96-week time point, 13/46 (28%) of patients had gained ≥15 letters and also demonstrated a mean reduction in CMT of 162 μm (SD 106) (p = < 0.0001), with 72% of maculae being fluid-free. Using univariate analysis, we found no significant difference between any of the visual outcome measures in this study and the pivotal VIEW study; the mean number of injections required and change in CMT were also similar. Conclusions: In this study, we present the 96-week results, of the largest series to date, of patients treated prospectively with aflibercept for RAP using the VIEW protocol. We show that they benefited from treatment to a degree similar to those with type 1 and 2 nAMD.
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Retinal angiomatous proliferation (RAP) is a distinct form of neovascular age-related macular degeneration (nAMD), first described by Yannuzzi et al. [1] in 2001, and later revised by Freund et al. [2] in 2008 with the entity being reclassified as type 3 neovascularisation in recognition of it being of a different pathological mechanism compared with type 1 and 2 neovascularisation (occult and classic lesions, respectively). The disorder is thought to occur in approximately 15-20% of cases of nAMD [2, 3] , and is characterised by initial intraretinal neovascularisation [4] . Compared with type 1 and 2 choroidal neovascularisation (CNV), the risk factors for RAP are thought to include older age, arterial hypertension, the ARMS2 gene risk allele, female sex, and the presence of reticular pseudodrusen [3, [5] [6] [7] [8] [9] . Untreated, RAP lesions are thought to be aggressive and have a poor visual outcome [10] . There also appears to be an increased rate of second-eye involvement, with up to 100% of fellow eyes being similarly affected within 3 years [9, 11] . Early treatments for RAP lesions were direct laser photocoagulation, and Verteporfin photodynamic therapy (alone and in combination with intravitreal triamcinolone), with limited long-term success [12] [13] [14] [15] [16] [17] . More recently, treatment with the intravitreal anti-VEGF drugs, ranibizumab and bevacizumab, has been met with generally favourable but variable responses [18] [19] [20] [21] [22] [23] . Unfortunately, many of these studies were limited by variation in treatments and follow-up protocols and were often retrospective in nature.
More recently, aflibercept was licensed to treat nAMD after the results of the pivotal VIEW studies were published [24, 25] . The clinical effect of this drug was equivalent to that of ranibizumab. Due to its higher binding affinity for VEGF, aflibercept offers a potential benefit of less frequent treatments and follow-up visits. To date, very little data has been presented on the long-term effectiveness of aflibercept in treating RAP lesions, with the few existing studies being limited by short a follow-up and small sample sizes [26] [27] [28] . We present the 96-week results of patients with Reading Centre-graded RAP lesions, who were treated with intravitreal aflibercept according to the treatment and follow-up protocols of the pivotal VIEW studies.
Materials and Methods
This was a prospective, interventional, single-centre study on patients with macular RAP lesions who presented to the macular clinic (where A.C.B, one of the authors, is based) and were naïve to treatment. Consecutive patients were recruited to the study if they fulfilled the NICE guidance for the treatment of nAMD with aflibercept (TA294) [29] . Briefly, they were to be older than 50 years, have a best-corrected visual acuity (BCVA) of between 73 and 25 ETDRS letters (6/12 and 6/96), no permanent structural damage to the central fovea and a lesion size of ≤12 disc areas in the greatest linear dimension, and evidence of recent presumed disease progression (as indicated by fluorescein angiography) or recent visual acuity changes [29, 30] .
A diagnosis of RAP was made if there was a focal area of intense, intraretinal hyper-fluorescence (a "hot spot") in the early phase of the fluorescein angiogram (FA), and a hot spot corresponding to the neovascular lesion that became increasingly hyper-fluorescent during the middle and late phases of the indocyanine green (ICG) angiogram, along with ≥1 of the following: focal intraretinal superficial haemorrhage, lipid exudate, fibro-vascular pigment epithelial detachment, and a retinal vascular abnormality, e.g., anastomosis between retinal vessels, retinal and choroidal vessels, or retinal vessels and the underlying CNV complex [1, 2, 18, 22, 31] .
The diagnosis was confirmed, and the RAP lesions were graded by the Central Angiographic Resource Facility, Queen's University, Belfast, UK, based on stereo colour photographs (Carl Zeiss, Cambridge, UK), stereo FA and ICG angiogram (HRA2, Heidelberg Engineering, Heidelberg, Germany) and macular OCT scans (Spectralis, Heidelberg Engineering) [1, 2, 9, 32] . The patients were treated using the VIEW 2q8 protocol, as this was shown to be effective in a phase-3 randomised controlled trial for the treatment of nAMD [24, 25] . This allowed for a direct comparison to be made between the response of the RAP lesions in this study and the type 1 and 2 lesions found in the VIEW study [33] .
No patient presented with simultaneous bilateral RAP lesions. If they subsequently went on to develop a lesion in the fellow eye during the follow-up period, only the first eye was included in the study. The patients received 2 mg of intravitreal aflibercept (Bayer, Basel, Switzerland) every 8 weeks, after 3 initial monthly injections, up to and including week 48. During weeks 52-96, they received injections at least every 12 weeks, with monthly evaluations for interim injections if there was new or persistent fluid on OCT scan, an increase in central macular thickness (CMT) of ≥100 μm, a loss of ≥5 ETDRS letters in conjunction with recurrent fluid on OCT, a new macular haemorrhage, or a time lapse of 12 weeks since the previous injection (capped p.r.n. protocol) [25] . At the baseline visit, patient demographics and past ocular history were recorded. The BCVA was recorded in both eyes using ETDRS charts at a 2-m distance as previously described [34] . The macula was evaluated by indirect ophthalmoscopy and OCT scans using a fast macula scan. The baseline OCT scan was used as the reference for subsequent visits using the Heidelberg registration software. A 30° 488-nm macular blue fundus autofluorescence (FAF) image was recorded at baseline and then every 6 months (Spectralis). At each subsequent visit, BCVA was recorded, and indirect ophthalmoscopy was performed as well as a macular OCT scan with reference to the baseline registration scan. The presence of reticular pseudodrusen at baseline was determined by one of the authors (A.C.B.) based on previous methods using a combination of OCT, infra-red reflectance, and FAF [35, 36] . Sub-foveal choroidal thickness (SFCT) was measured at baseline in the affected eyes by means of the fast macular scan in the enhanced depth imaging (EDI) mode by 2 independent examiners (R.G. and J.M.O.) who were masked to the patient's demo- graphics or outcomes. The SFCT was defined as the mean measurement from the outer aspect of the basement membrane to the inner surface of the sclera, by using callipers with the Heidelberg software on magnified OCT horizontal scans passing through the fovea. An age-matched control group of Caucasian patients undergoing cataract surgery with AREDS category 1 AMD or less [37] and who had a normal axial length (22.0-24.5 mm) were used to establish a local normal range for SFCT. The left eyes of the control subjects were used to calculate the age-matched normal range.
Outcome Measures
Similar to the VIEW study, the primary end point was the number of patients maintaining visual acuity (losing < 15 ETDRS letters at weeks 52 and 96). Secondary end points were: the proportion of patients gaining ≥15 letters at weeks 52 and 96, the mean change in central retinal thickness from baseline to week 96, the proportion of patients without retinal fluid at weeks 52 and 96, and the mean number of study drug injections up to week 96.
Statistical Analysis
We compared our results to those of the published outcomes from the VIEW2 2q8 arm of the pivotal VIEW studies [24, 25] . The Student paired t test was used to compare the differences between BCVA or CMT at baseline and other time points and the Student unpaired t test was used for comparing the differences between axial lengths and SFCT in the patient and control groups. As recommended by Peduzzi et al. [38] , we followed the rule of including 1 covariate in the model for each 10 outcome events, which only allowed us to perform univariate logistic regression analysis to investigate the relationship between individual aspects of the patients' baseline demographics and a favourable visual outcome (> 15 ETDRS letters gained). The results were presented as odds ratio (OR) and 95% confidence interval (CI), and statistical significance was assumed when the CI included 1. The proportions of individuals with a loss or a gain of ≥15 letters at 52 and 96 weeks in this study and the VIEW study were compared by means of the Fisher exact test. Data analysis was performed by using SPSS v22 and R v3.5.1.
Results
In total, 53 patients fulfilled the inclusion criteria and were recruited to the study between January 2014 and August 2015. Six patients withdrew early (4 due to serious illness and 2 due to endophthalmitis) and 1 died. Neither of the patients who developed endophthalmitis had any predisposing factors and the departmental rate at the time of the study was > 0.033%. Forty-six patients reached study completion at week 96. The patients that completed the study were all Caucasian, with a mean age of 81.5 (range 67-97) years. There were 34 females (74%) and 29 left eyes (63%). Table 1 compares the baseline demographics of our patients and those in the 2q8 treatment arm of the VIEW study. At baseline, 7 patients were diabetic (15%), 10 were current smokers (22%), 27 were on treatment for hypertension (59%), 5 were taking clopidogrel (11%), and 18 eyes were pseudophakic (39%). The mean duration of symptoms prior to the initiation of treatment was 7.8 weeks (range 4 days to 52 weeks). In the affected eye, 39/46 (85%) of maculae had evidence of reticular pseudodrusen, the mean SFCT was 160 μm (SD 48 μm), and the mean axial length was 23.2 mm (SD 0.93 mm). In an age-matched control group of 25 patients undergoing cataract surgery, the mean SFCT was 156 μm (SD 38 μm) and mean axial length 23.5 mm (SD 0.93 mm). There was no significant difference in the SFCT or axial length in the eyes of the RAP patients and controls (p = 0.8 and p = 0.1, respectively).
The correlation (r s ) of SFCT measurements taken by the 2 observers for RAP eyes and control eyes was 0.75 (p < 0.001) and 0.92 (p < 0.001), respectively.
Reading Centre grading of the RAP lesions revealed that 3 (6%) were stage 1, 9 (20%) were stage 2, and 34 (74%) were stage 3. At baseline, the fellow eye had evidence of pre-existing nAMD or disciform scarring in 14 patients (30%). In 1 case, it was impossible to evaluate the fellow eye due to a long-standing retinal detachment and dense cataract. Of the remaining 31 eyes, 13 (42%) had developed a new angiographically confirmed RAP lesion by week 96. There were no instances of torn retinal pigment epithelium (RPE) during the follow-up period.
Mean BCVA improved by 6.0 (SD 7.9) and 4.8 (SD 7.4) ETDRS letters at 52 and 96 weeks, respectively, from a baseline of 57.3 (SD 12.0) letters (p = 0.03 and p = 0.02, respectively). The change in mean BCVA over time is shown in Figure 1 . The largest improvement in BCVA was seen early in the course of treatment, with a peak gain of 8 letters at 20 weeks. At 52 weeks, 45/46 (98%) of patients had maintained their vision (< 15 letters of BCVA had been lost), while 10/46 (22%) had gained ≥15 letters. At the 96-week time point, 41 (89%) had maintained their BCVA while 13 (28%) had gained ≥15 letters. Of the 5 patients who lost ≤15 letters at week 96, 4 cases were due to central foveal photoreceptor atrophy and 1 was due to extensive scarring after a sub-macular haemorrhage. The mean CMT was reduced by 135 μm (SD 118 μm) at 4 weeks from a mean of 438 μm at baseline (SD 105) (p = < 0.0001). At 52 weeks, the mean CMT was reduced by 165 μm (SD 156 μm) (p = < 0.0001) with 83% of maculae being fluid-free, while at week 96, there was a mean reduction in CMT of 162 μm (SD 106 μm) (p = <0.0001) with 72% of maculae being fluidfree. The change in mean CMT over time is shown in Figure 2 .
Due to the small number of patients with a poor visual outcome, it was not possible to perform univariable or multivariable analyses to determine factors associated with a poor outcome. There were more patients with a favourable outcome (> 15 letters gained in BCVA) and it was possible to perform univariable analysis on these patients. We found no evidence of an effect of age, sex, lesion stage at baseline, symptom duration prior to treatment, smoking, diabetes, or cardiovascular disease on a favourable visual outcome at weeks 52 and 96 ( Table 2 ). The outcomes of the 2q8 VIEW 2 study group and our RAP cohort are compared in Table 3 . It can be seen that the proportion of patients with stable vision and those gaining > 15 letters was similar in the 2 groups. There was no statistically significant difference in any visual outcomes in the 2 studies (p > 0.05 for all comparisons using the Fisher exact test); the mean number of injections required and the mean change in CMT in each group were also similar.
Conclusion
This study demonstrates that a fixed dosing schedule of aflibercept in the first year followed by a capped p.r.n. protocol in the second year, i.e., replicating the pivotal VIEW study protocol, was an effective treatment for type 3 neovascularisation or RAP. Our outcomes corroborate the results of the subgroup analysis of the CATT trial which showed that the outcome of RAP lesions treated with either ranibizumab or bevacizumab were similar to type 1 and 2 wet AMD lesions without RAP at 2 years, irrespective of the protocol or drug used [18] . Other prospective studies investigating the effect of the anti-VEGF agents ranibizumab and bevacizumab on RAP lesions have also demonstrated that these drugs appear to stabilise or improve visual acuity and reduce macular thickness at 2 years of follow-up [6, 20, 22, 39] .
Aflibercept was approved in the UK for the treatment of nAMD in 2013. It has a higher affinity for VEGF-A and a longer half-life, which offers the hope of a longer duration of action; it also blocks the action of placental growth factor. Because RAP lesions may represent an aggressive subtype of nAMD with a potentially poor visual prognosis, it was suggested that the properties above may be useful in the treatment of RAP [26] . In 2014, Tsaousis et al. [26] were the first to show that aflibercept may be beneficial in treating RAP lesions. They reported the 4-month follow-up results of 12 eyes with stage 1 and 2 RAP lesions treated with 3-monthly loading doses of aflibercept. They found a 0.14 log MAR improvement in BCVA and a significant reduction in CMT. Their study was limited by a short follow-up and a small sample size. A larger prospective study on the effect of aflibercept, published in 2015 by Oishi et al. [28] , demonstrated that, in a small sub group of AMD patients diagnosed with RAP and treated as per the VIEW study year 1 protocol, there was a non-significant improvement in BCVA. Finally, a significant improvement in BCVA and a reduction in CMT at 12 months was shown in a small retrospective study on 17 patients published in 2016 by Matsumoto et al. [27] ; patients were subjected to a loading phase with aflibercept, followed by a treat-andextend phase of treatment. Unfortunately, to date, there are no published prospective, large-scale clinical studies of intravitreal aflibercept using a treat-and-extend regi- men for nAMD, although this may change in the future [40] . Our study demonstrated a rapid improvement in vision after treatment initiation, reaching a peak of 8 ET-DRS letters at week 24, while maximum a CMT reduction was seen at week 8. Interestingly, the mean CMT reduction was less between weeks 16 and 48, which coincided with the period of bimonthly treatment. After this period, the capped p.r.n. protocol, re-established the maximum reduction in CMT. This would indicate that during the bimonthly period, the lesions retained some residual activity, and that bimonthly treatment may therefore be sub-optimal. This theory is given added credence when one looks at the study of Kim et al. [41] . Although their study was retrospective in nature, and most patients received ranubizumab instead of aflibercept, they used an essentially p.r.n. protocol after an initial loading phase of 12 months. They found a significantly worse outcome for stage 3 lesions (even when dry on OCT) compared to stage 2 lesions. Compared with our study in which all patients received 8 aflibercept injections in the first 12 months, their cases received 4.2 and 4.6 injections for stage 2 and 3 lesions, respectively. Three out of 26 (12%) of their stage 3 lesions also developed visually significant RPE tears during follow-up compared with no cases of torn RPE in our study. Based on our findings, this would suggest that the stage 3 lesions were undertreated in their study, providing further evidence that RAP lesions require intensive treatment, certainly during the first 12 months of follow-up at least.
Despite the maintenance of maximum CMT reduction after week 48, BCVA gain gradually declined from 8 letters at week 24 to 4.9 letters at week 96. The reason for this decline is unknown, but may have been due to progressive RPE atrophy, known to be more commonly associated with RAP lesions [42, 43] or else the accumulation of photoreceptor damage caused by earlier sub-optimal treatment.
The percentage of eyes with stable vision and a gain of ≥15 letters and the number of injections given over 2 years were similar in this study and the VIEW trial [25] . Interestingly, more patients were fluid-free at week 96 in our RAP cohort than in the non-RAP lesions in the VIEW study (74 vs. 50%). This finding was also found in the CATT subgroup analysis [18] . Like other researchers, we found that patients with RAP were older and more likely to have reticular pseudodrusen at baseline compared to type 1 and 2 wet AMD patients. However, unlike other researchers, we found no difference in the subfoveal choroidal thickness at baseline in our RAP patients and their age-matched controls, although our patients were of a different racial group from those in previously published studies [44, 45] . In comparison to other researchers, we found no association of favourable treatment outcome with lesion stage [46] or symptom duration prior to treatment, as is seen in type 1 and 2 nAMD [47] . This may have been due to the effect of a skewed distribution of lesion stages within our group (mostly stage 3) and/or the relatively small study sample. Baseline smoking status, diabetes, or the presence of psudophakia, also appeared to not affect visual outcome. In a recent post hoc analysis of the visual outcomes of the VIEW study, better visual gain was associated with younger age, worse initial vision, smaller CNV size, and certain CNV subtypes at baseline [33] . Interestingly, no RAP lesions were reported in the analysis, even though they would be expected to make up some cases of nAMD.
In cases of unilateral RAP, we found that a similar lesion had developed in the fellow eye in 42% of cases by week 96. This is similar to the results reported by Gross et al. [9] , who found that 52% of patients developed RAP in the fellow eye over 2 years.
This study has the strength that it is the largest series to date of treatment-naïve RAP patients undergoing prospective treatment with aflibercept. In addition, all patients were reviewed within the time scales of the VIEW study protocol and underwent a BCVA log MAR measurement at each visit. The diagnosis of RAP was also confirmed and graded by an independent reading centre. Disadvantages include the absence of a true control group and the relatively small number of patients recruited; these reduce the power to detect an effect of baseline demographics and lesion characteristics on outcomes. In summary, we present the long-term results of the largest series to date of patients treated prospectively with aflibercept for RAP. We show that they benefited from treatment to a degree similar to those with type 1 and 2 nAMD up to week 96 [33] .
